TABLE 2.

Toxicities Observed During Concurrent Chemoradiotherapy in Arm A (Cisplatin-Etoposide-Erlotinib-Radiotherapy) and Arm B (Carboplatin-Paclitaxel-Erlotinib-Radiotherapy)

	Hemoglobin		WBC		ANC		Platelets		Esophagitis		Vomiting		Neuropathy		Diarrhea		Rash		Radiation Dermatitis		Others
Grade	1/2	3/4	1/2	3/4	1/2	3/4	1/2	3/4	1/2	3/4	1/2	3/4	1/2	3/4	1/2	3/4	1/2	3/4	1/2	3/4	1/2	3/4
Arm A
Level 1 (n = 4)	4(100%)		1(25%)	3(75%)	1(25%)	3(75%)	1(25%)	1(25%)	1(25%)	2(50%)		1(25%)	1(25%)			1(25%)			1(25%)			1 Pneu
Level 2 (n = 3)	2(67%)		1(33%)	2(67%)		2(67%)		3(100%)	2(67%)		2(67%)				2(67%)				2(67%)
Level 3 (n = 9)	6(67%)		2(22%)	4(44%)	4(44%)	3(33%)	6(67%)	1(11%)	5(56%)	1(11%)	1(11%)		4(44%)		4(44%)	1(11%)	3(33%)		3(33%)			1 Otox
Arm B
Level 1 (n = 5)	2(40%)		2(40%)	1(20%)	1(20%)	1(20%)	1(20%)	1(20%)	5(100%)		3(60%)		2(40%)				2(20%)
Level 2 (n = 3)	2(67%)		2(67%)		1(33%)	1(33%)	2(67%)		1(33%)	2(67%)			2(67%)				1(33%)
Level 3 (n = 7)	7(100%)		2(29%)	4(57%)	4(57%)	1(14%)	3(43%)	1(14%)	3(43%)	4(57%)	3(43%)		2(29%)		5(71%)		1(14%)		2(29%)

Pneu, Radiation pneumonitis; Otox, Otoxicity.

Underlined-italic font indicates dose-limiting toxicity.